Basilea Pharmaceutica (FRA:PK5) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


FRA:PK5 Basilea Pharmaceutica Ltd FRA:PK5
62 GF Score
Price €56.30
GF Value €60.85
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Basilea Pharmaceutica's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:PK5 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Basilea Pharmaceutica's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Basilea Pharmaceutica Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Margin of Safety % (DCF Earnings Based) falls into.


FRA:PK5
62GF Score
Basilea Pharmaceutica Ltd FRA:PK5
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Basilea Pharmaceutica (FRA:PK5) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of €56.30 is trading 7.5% below its estimated GF Value™ of €60.85. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for FRA:PK5:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €60.85 vs. price of €56.30 (7.5% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the FRA:PK5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score

Get the complete analysis for FRA:PK5

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.30
Price
€60.85
GF Value